You are here

Press Release Archive

 
February 26, 2015 - CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Pfizer Inc. (NYSE: PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk. Specifically, the ACIP voted to recommend serogroup B meningococcal vaccination for persons aged 10 years and older at increased risk for meningococcal disease, including:

 
February 20, 2015 - FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA)for RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease in women of childbearing age that is often fatal.

 
February 13, 2015 - Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride), extended-release capsules, an abuse-deterrent formulation (ADF) opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release oxycodone specifically designed to reduce abuse via the oral, intranasal (i.e., snorting) and intravenous (IV) routes when crushed.

 
February 12, 2015 - Safety and Efficacy of ELELYSO® (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015

Pfizer Inc. (NYSE: PFE) today announced that researchers presented new data which expand on the existing body of data for ELELYSO (taliglucerase alfa) for injection in pediatric patients with Type 1 Gaucher disease.  These data, which were released today in an oral presentation at the 11th Annual WORLDSymposium in Orlando, include results from a Phase 3, multi-center, extension trial evaluating the long-term efficacy and safety of ELELYSO in pediatric patients with Type 1 Gaucher disease who were treatment-naïve or previously treated with imiglucerase. 

 
February 5, 2015 - Pfizer to Acquire Hospira

Pfizer Inc. (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion. 

 
February 5, 2015 - Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer's Proposed Acquisition of Hospira

Pfizer will hold an analyst and investor call to discuss its proposed acquisition of Hospira at 9:00 AM EST (2:00 PM GMT) today, February 5, 2015. Pfizer will also hold a media call at 10:15 AM EST (3:15 PM GMT) today, February 5, 2015.

 
February 4, 2015 - Pfizer Marks World Cancer Day With Grant To Union For International Cancer Control To Address The Needs Of Metastatic Breast Cancer Patients

Pfizer Inc. today announced a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients.

 
February 3, 2015 - Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib)

Pfizer Inc. today announced the U.S.

 
January 27, 2015 - PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

 
January 26, 2015 - Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025

Pfizer Inc. (NYSE:PFE) today announced new commitments aimed at ensuring the world’s most resource-limited countries have access to Prevenar 13* (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, absorbed) through Gavi, the Vaccine Alliance. Pfizer’s commitments were announced during Gavi’s pledging conference being held in Berlin, Germany, in support of Gavi’s 2016 – 2020 strategy.

 
January 21, 2015 - Pfizer and the Avon Foundation for Women Award 23 Grants Totaling $1 Million in Funding to Support Patients Living With Metastatic Breast Cancer

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify.

 
January 8, 2015 - Pfizer Provides Update on IBRANCE® (palbociclib)

The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc.

 
January 5, 2015 - Pfizer Acquires Redvax GmbH

Pfizer Inc. today announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.